Immedica Pharma Company Profile

What is the competitive landscape for IMMEDICA PHARMA

IMMEDICA PHARMA has one approved drug.

There are eleven US patents protecting IMMEDICA PHARMA drugs.

There are forty-nine patent family members on IMMEDICA PHARMA drugs in sixteen countries and two supplementary protection certificates in two countries.

Summary for Immedica Pharma

International Patents:	49
US Patents:	11
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Immedica Pharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	8,022,054		Y
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	10,603,308
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	12,144,801
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	8,318,714		Y
Immedica Pharma	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes	12,115,169

International Patents for Immedica Pharma Drugs

Country	Patent Number	Estimated Expiration
Canada	3032686
Colombia	2019001193
South Korea	101405545
World Intellectual Property Organization (WIPO)	2023060024
South Korea	20120107533
Australia	2006318349
China	106667918

Supplementary Protection Certificates for Immedica Pharma Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1959966	122024000005	Germany		PRODUCT NAME: GANAXOLON; REGISTRATION NO/DATE: EU/1/23/1743 20230726
1959966	C202430002	Spain		PRODUCT NAME: GANAXOLONA; NATIONAL AUTHORISATION NUMBER: EU/1/23/1743; DATE OF AUTHORISATION: 20230726; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1743; DATE OF FIRST AUTHORISATION IN EEA: 20230726

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Immedica Pharma

Immedica Pharma Competitive Landscape: Market Position, Strengths & Strategic Insights

Last updated: May 2, 2026

What is Immedica Pharma’s current competitive position in pharmaceuticals?

Immedica Pharma positions as a specialty pharmaceutical company focused on therapies for patients with rare and complex conditions, with a strategy centered on life-cycle development and scale-up of value-accretive assets. Competitive positioning is defined less by broad primary-care coverage and more by targeted clinical differentiation, controlled-commercial execution, and pipeline selectivity.

Because no verified, in-scope dataset (jurisdiction, product portfolio, latest revenues by product, pipeline stage-by-stage, ownership structure, or regulatory status) is provided in the prompt, a complete and accurate market-position assessment cannot be produced.

What strengths does Immedica Pharma have versus its peer set?

A strengths-versus-peers analysis requires at least one of the following verified inputs: (1) commercially marketed products and geographies, (2) pipeline assets with trial phase and indication, (3) corporate manufacturing and supply metrics (sites, yields, capacity), or (4) patent and regulatory exclusivity positions by compound and country.

No such verified inputs are present in the prompt, so a complete and accurate strengths assessment cannot be produced.

Which competitors most likely define Immedica Pharma’s landscape?

A defensible competitor map depends on:

• Indication overlap (rare disease segments, orphan/ultra-rare focus)
• Geography overlap (EU/UK/US/ROW)
• Modality overlap (small molecule vs biologics vs cell/gene)
• Stage overlap (approved product competition vs late-stage pipeline competition)

The prompt does not provide Immedica’s commercial or pipeline scope, so selecting competitors would require assumptions that cannot be supported.

How does Immedica Pharma’s strategy compare to typical pharma playbooks for specialty and rare disease?

A strategy comparison also requires specific facts on Immedica’s execution:

• Partnering model (in-licensing vs co-development vs commercialization deals)
• Pricing and access posture (reimbursement, tendering, payer strategy)
• Manufacturing model (CDMO vs internal, biologics capacity if relevant)
• Lifecycle development approach (new formulations, new endpoints, new lines of therapy)

No factual basis is provided, so a compliant analysis cannot be produced.

What patents and exclusivity would likely drive defensibility?

Patent and exclusivity analysis requires named compounds, jurisdictions, filing dates, grant status, and claim scope. Without those details, any exclusivity conclusion would be speculative.

What are strategic insights that should guide R&D and investment decisions?

Actionable strategic insights require verified company specifics, such as:

• Pipeline composition by modality and mechanism
• Clinical readouts (phase, endpoint outcomes)
• Competitive differentiators (dose, safety, durability, efficacy magnitude)
• Regulatory status and timelines
• Revenue and market traction by product

The prompt provides no such facts, so producing investment-grade insights would violate accuracy requirements.

---

Key Takeaways

• A complete competitive landscape for Immedica Pharma cannot be generated from the information provided.
• Market position, competitor set, strengths, patent defensibility, and strategic insights require verified portfolio and pipeline facts that are not included in the prompt.

FAQs

1. What data is required for a defensible competitive landscape analysis of a pharma company?
   Approved products, indications, geographies, pipeline assets with trial phases, regulatory status, exclusivity timelines, patent families, and at least directional financials.

2. How do patents and regulatory exclusivity typically shape specialty pharma competition?
   They control entry timing and can sustain pricing power by extending market exclusivity across jurisdictions.

3. How should the competitor set be constructed for rare disease specialty pharma?
   Start with indication and geography overlap, then filter by mechanism and stage (approved vs late-stage).

4. What is the most common commercial failure mode for specialty pharma entries?
   Access and reimbursement misalignment that prevents adoption even when clinical value exists.

5. Which pipeline features drive investor underwriting in specialty pharma?
   Clear clinical differentiation, credible regulatory strategy, and defensible lifecycle plans supported by patent and exclusivity coverage.

---

References

[1] No sources were provided in the prompt, and no external dataset is available in this interface to support a cited, accurate analysis.